

Hemophilia A

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A

Trial Status
Recruiting

Trial Runs In
6 Countries

Trial Identifier
NCT05987449 2023-503906-35-00
WP44714

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

Study WP44714 is a Phase I/II, open-label, non-randomized, global, multicenter, multiple-ascending dose (MAD) study in adult and adolescent male participants with severe or moderate hemophilia A with or without factor VIII (FVIII) inhibitors. The aim is to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of multiple ascending doses of NXT007.

Hoffmann-La Roche
Sponsor

Phase 1/Phase 2
Phase

NCT05987449 2023-503906-35-00 WP44714
Trial Identifiers

Eligibility Criteria:

Gender
Male

Age
≥12 Years & ≤ 59 Years

Healthy Volunteers
No